1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
LTR Pharma Limited

LTR Pharma Limited

LTP.AX
LTR Pharma LimitedAU flagAustralian Securities Exchange
0.44
AUD
- -
- -
80.20MMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-0.01
-0.01
-0.05
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
- -
0.01
0.05
0.02
0.17
Tangible Book Value per Share
- -
0.01
0.05
0.02
0.17
Basic Weighted Avg Shares
139
139
139
139
167
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
-5,123.89
Depreciation Expense
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-1
-1
-7
-6
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
-3,837.01
Working Capital
- -
1
7
3
31
LT Debt
- -
- -
- -
- -
- -
Total Equity
- -
2
7
3
32
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-31.43
-133.37
-32.47

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
971.58%
Free Cash Flow
- -
- -
566.4%
Net Income, GAAP
- -
- -
-19.57%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.05
2025
- -
- -
- -
- -
-0.03

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
Sector
Healthcare
Industry
Biotechnology
Address
29/97 Creek Street Brisbane QLD Australia 4000
IPO Date
Dec 10, 2023
Website
ltrpharma.com
Similar Companies
Emmaus Life Sciences, Inc. (EMMA)
Ehouse Global, Inc. (EHOS)
Immunotech Laboratories, Inc. (IMMB)
Nuvalent, Inc. (NUVL)
Tonix Pharmaceuticals Holding Corp. (TNXP)
CellSeed Inc. (7776.T)
Business
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.